1633

524494

IPCALAB

img img img img
No Data Available

IPCA LABORATORIES LTD Share Price Update

As of the latest trading session, IPCA LABORATORIES LTD is trading at ₹1524.4, down by ₹-48.00 or -3.05% from its previous close. The stock has moved between ₹1482.90 and ₹1618.70 today. Over the past year, the stock has delivered a return of 3.70%. In the last month, it has returned -1.14%.

IPCA LABORATORIES LTD performance

Today’s low Today’s high
₹ 1482.90 ₹ 1618.70
₹ 1524.40
52 week low 52 week high
₹ 1251.60 ₹ 1678.30
₹ 1524.40
Open Price ₹ 1576.90
Prev. Close ₹ 1572.40
Volume (Shares) 979166.00
Total traded value ₹ 14926.40
Upper Circuit ₹ 1886.80
Lower Circuit ₹ 1258.00
info

Investment Returns

Over 1 Month -1.14% Over 3 Months 0.75% Over 6 Months 7.30% Over 1 Year 3.70%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

IPCA LABORATORIES LTD fundamentals


  • Market cap (Cr) 38,674.70
  • P/E Ratio (TTM) 47.67
  • Beta 0.03
  • Book Value / share 291.98
  • Return on equity 12.39%
  • EPS (TTM) 39.59
  • Dividend yield 0.26%
  • Net profit/quarter (Cr) 262.29
info icon alternate text
  • Market cap (Cr) 38,382.90
  • P/E Ratio (TTM) 47.67
  • Beta -0.02
  • Book Value / share 291.98
  • Return on equity 12.39%
  • EPS (TTM) 39.59
  • Dividend yield 0.26%
  • Net profit/quarter (Cr) 262.29
info icon alternate text

IPCA LABORATORIES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 1814.35
Operating Expense 1463.96
Net Profit 262.29
Net Profit Margin (%) 14.45
Earnings Per Share (EPS) 11.54
EBITDA 430.64
Effective Tax Rate (%) 25.02
Particulars DEC 2025 (Values in Cr)
Revenue 1845.18
Operating Expense 1445.78
Net Profit 303.45
Net Profit Margin (%) 16.44
Earnings Per Share (EPS) 11.96
EBITDA 495.30
Effective Tax Rate (%) 27.26
Particulars SEP 2025 (Values in Cr)
Revenue 1930.32
Operating Expense 1543.93
Net Profit 304.74
Net Profit Margin (%) 15.78
Earnings Per Share (EPS) 12.01
EBITDA 486.63
Effective Tax Rate (%) 25.36
Particulars JUN 2025 (Values in Cr)
Revenue 1746.90
Operating Expense 1415.16
Net Profit 262.04
Net Profit Margin (%) 15.00
Earnings Per Share (EPS) 10.33
EBITDA 431.94
Effective Tax Rate (%) 26.54
Particulars MAR 2025 (Values in Cr)
Revenue 1638.44
Operating Expense 1361.24
Net Profit -65.05
Net Profit Margin (%) -3.97
Earnings Per Share (EPS) -2.56
EBITDA 98.53
Effective Tax Rate (%) 479.30
Particulars MAR 2026 (Values in Cr)
Revenue 7336.75
Operating Expense 5868.84
Net Profit 1132.52
Net Profit Margin (%) 15.43
Earnings Per Share (EPS) 45.84
EBITDA 1844.51
Effective Tax Rate (%) 26.08
Particulars MAR 2025 (Values in Cr)
Revenue 6677.92
Operating Expense 5467.90
Net Profit 650.76
Net Profit Margin (%) 9.74
Earnings Per Share (EPS) 25.65
EBITDA 1314.78
Effective Tax Rate (%) 34.90
Particulars MAR 2024 (Values in Cr)
Revenue 6166.46
Operating Expense 5322.23
Net Profit 530.41
Net Profit Margin (%) 8.60
Earnings Per Share (EPS) 20.91
EBITDA 1189.31
Effective Tax Rate (%) 35.48
Particulars MAR 2023 (Values in Cr)
Revenue 5814.62
Operating Expense 5175.32
Net Profit 505.70
Net Profit Margin (%) 8.69
Earnings Per Share (EPS) 19.93
EBITDA 1023.04
Effective Tax Rate (%) 32.61
Particulars MAR 2022 (Values in Cr)
Revenue 5438.30
Operating Expense 4417.11
Net Profit 860.37
Net Profit Margin (%) 15.82
Earnings Per Share (EPS) 33.91
EBITDA 1291.00
Effective Tax Rate (%) 19.89
Particulars MAR 2025 (Values in Cr)
Book Value / Share 273.88
ROE % 13.61
ROCE % 17.12
Total Debt to Total Equity 0.21
EBITDA Margin 20.02
Particulars MAR 2024 (Values in Cr)
Book Value / Share 249.59
ROE % 8.69
ROCE % 12.92
Total Debt to Total Equity 0.24
EBITDA Margin 17.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 230.27
ROE % 8.70
ROCE % 11.59
Total Debt to Total Equity 0.20
EBITDA Margin 16.90
Particulars MAR 2022 (Values in Cr)
Book Value / Share 215.41
ROE % 17.92
ROCE % 20.26
Total Debt to Total Equity 0.11
EBITDA Margin 23.66
Particulars MAR 2021 (Values in Cr)
Book Value / Share 370.65
ROE % 27.59
ROCE % 30.56
Total Debt to Total Equity 0.09
EBITDA Margin 29.71
Particulars MAR 2025 (Values in Cr)
Book Value / Share 271.64
ROE % 12.39
ROCE % 17.21
Total Debt to Total Equity 0.16
EBITDA Margin 23.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 250.24
ROE % 9.81
ROCE % 14.12
Total Debt to Total Equity 0.21
EBITDA Margin 21.08
Particulars MAR 2023 (Values in Cr)
Book Value / Share 231.66
ROE % 8.91
ROCE % 11.67
Total Debt to Total Equity 0.20
EBITDA Margin 17.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 215.84
ROE % 16.82
ROCE % 19.15
Total Debt to Total Equity 0.10
EBITDA Margin 23.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 374.67
ROE % 27.06
ROCE % 30.20
Total Debt to Total Equity 0.08
EBITDA Margin 30.72
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 344.23
Total Assets 11760.55
Total Liabilities 11760.55
Total Equity 8388.27
Share Outstanding 25
Price to Book Ratio 5.53
Return on Assets (%) 6.27
Return on Capital (%) 7.61
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 296.84
Total Assets 11101.28
Total Liabilities 11101.28
Total Equity 7727.00
Share Outstanding 25
Price to Book Ratio 4.95
Return on Assets (%) 4.93
Return on Capital (%) 6.01
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1853.24
Total Assets 8626.43
Total Liabilities 8626.43
Total Equity 5915.32
Share Outstanding 25
Price to Book Ratio 3.50
Return on Assets (%) 5.46
Return on Capital (%) 6.39
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 640.66
Total Assets 7623.53
Total Liabilities 7623.53
Total Equity 5541.76
Share Outstanding 25
Price to Book Ratio 4.92
Return on Assets (%) 11.59
Return on Capital (%) 13.96
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 365.07
Total Assets 6068.36
Total Liabilities 6068.36
Total Equity 4716.18
Share Outstanding 12
Price to Book Ratio 5.08
Return on Assets (%) 18.78
Return on Capital (%) 22.94
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 164.53
Total Assets 9070.92
Total Liabilities 9070.92
Total Equity 6891.62
Share Outstanding 25
Price to Book Ratio 5.53
Return on Assets (%) 7.17
Return on Capital (%) 8.38
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 112.92
Total Assets 8659.27
Total Liabilities 8659.27
Total Equity 6348.71
Share Outstanding 25
Price to Book Ratio 4.95
Return on Assets (%) 6.12
Return on Capital (%) 7.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1706.06
Total Assets 8446.97
Total Liabilities 8446.97
Total Equity 5877.30
Share Outstanding 25
Price to Book Ratio 3.50
Return on Assets (%) 5.98
Return on Capital (%) 6.93
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 595.50
Total Assets 7438.44
Total Liabilities 7438.44
Total Equity 5475.76
Share Outstanding 25
Price to Book Ratio 4.92
Return on Assets (%) 11.56
Return on Capital (%) 13.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 306.92
Total Assets 6010.13
Total Liabilities 6010.13
Total Equity 4752.72
Share Outstanding 12
Price to Book Ratio 5.08
Return on Assets (%) 18.98
Return on Capital (%) 22.93
Particulars MAR 2025 (Values in Cr)
Net Income 1131.14
Cash from Operations 1682.57
Cash from Investing -869.50
Cash from Financing -282.98
Net change in Cash 168.84
Free Cash Flow 2458.09
Particulars MAR 2024 (Values in Cr)
Net Income 842.67
Cash from Operations 1240.95
Cash from Investing -1291.79
Cash from Financing -552.55
Net change in Cash -899.69
Free Cash Flow 1651.55
Particulars MAR 2023 (Values in Cr)
Net Income 745.29
Cash from Operations 1029.46
Cash from Investing -725.00
Cash from Financing 507.24
Net change in Cash 588.05
Free Cash Flow 1523.93
Particulars MAR 2022 (Values in Cr)
Net Income 1135.72
Cash from Operations 1058.11
Cash from Investing -855.05
Cash from Financing 426.78
Net change in Cash 427.80
Free Cash Flow 1537.06
Particulars MAR 2021 (Values in Cr)
Net Income 1388.98
Cash from Operations 1335.72
Cash from Investing -520.69
Cash from Financing -305.82
Net change in Cash 263.62
Free Cash Flow 1697.27
Particulars MAR 2025 (Values in Cr)
Net Income 999.77
Cash from Operations 1698.82
Cash from Investing -738.81
Cash from Financing -428.44
Net change in Cash 206.82
Free Cash Flow 2301.42
Particulars MAR 2024 (Values in Cr)
Net Income 822.16
Cash from Operations 1107.46
Cash from Investing -1355.18
Cash from Financing -464.88
Net change in Cash -989.55
Free Cash Flow 1467.68
Particulars MAR 2023 (Values in Cr)
Net Income 750.49
Cash from Operations 977.54
Cash from Investing -709.61
Cash from Financing 506.38
Net change in Cash 559.06
Free Cash Flow 1414.40
Particulars MAR 2022 (Values in Cr)
Net Income 1074.11
Cash from Operations 1023.88
Cash from Investing -814.00
Cash from Financing 426.04
Net change in Cash 443.76
Free Cash Flow 1475.51
Particulars MAR 2021 (Values in Cr)
Net Income 1379.96
Cash from Operations 1337.93
Cash from Investing -559.56
Cash from Financing -307.38
Net change in Cash 229.12
Free Cash Flow 1687.58
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.69 14.75 1.72 273.50 23.12 40.00
BLISS GVS PHARMA LTD. 424.80 34.37 3.76 4493.92 118.35 437.40
CIPLA LTD 1398.50 27.69 3.28 112970.91 1165.55 1672.20
FERMENTA BIOTECH LTD. 295.20 13.02 2.13 868.80 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.69 24.96 4.59 273.50 23.12 40.00
AMRUTAJAN HEALTH LTD 559.55 25.08 4.36 1617.69 490.00 789.95
ASTRAZENECA PHARMA IND LT 8671.45 113.25 24.83 21678.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 424.80 45.68 3.89 4493.92 118.35 437.40

IPCA LABORATORIES LTD shareholding pattern

Holding
7.19%
44.72%
10.63%
37.44%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

IPCA LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1524.40 -3.05 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 1566.80
  • 26 Days 1563.40
  • 10 Days 1577.90
  • 50 Days 1541.30
  • 12 Days 1577.70
  • 100 Days 1508.40
  • 20 Days 1570.10
  • 200 Days 1471.90
1577.27 PIVOT
First Support 1562.13 First Resistance 1587.53 Second Support 1551.87 Second Resistance 1602.67 Third Support 1536.73 Third Resistance 1612.93
RSI 42.81 ADX 47.35 MACD 14.36 Williams % R -78.76 Commodity Channel Index (CCI) -68.64
Date 2026-05-29 Week 96881.00 Same Day 299751.00 Month 165864.00
1 Year 0.04 3 Year 0.44
Over 1 Month
-1.14% down
Over 1 Year
3.70% down
Over 3 Months
0.75% down
Over 3 Years
30.29% down
Over 6 Months
7.30% down
Over 5 Years
8.04% down

IPCA LABORATORIES LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
05 Aug 2025 2.0 Final 05 Aug 2025 Equity shares
27 Nov 2024 2.0 Interim 27 Nov 2024 Equity shares
06 Aug 2024 2.0 Final 07 Aug 2024 Equity shares
22 Nov 2023 2.0 Interim 22 Nov 2023 Equity shares
22 Nov 2022 4.0 Interim 23 Nov 2022 Equity shares
22 Nov 2021 8.0 Interim 23 Nov 2021 Equity shares
13 Nov 2020 8.0 Interim 17 Nov 2020 Equity shares
18 Feb 2020 5.0 Interim 20 Feb 2020 Equity shares
06 Aug 2019 3.0 Final 08 Aug 2019 Equity shares
02 Aug 2018 1.0 Final 04 Aug 2018 Equity shares
27 Jul 2017 1.0 Final 29 Jul 2017 Equity shares
22 Jul 2015 1.0 Final 24 Jul 2015 Equity shares
18 Jul 2014 2.5 Final 22 Jul 2014 Equity shares
31 Oct 2013 2.5 Interim 01 Nov 2013 Equity shares
19 Jul 2013 2.0 Final 23 Jul 2013 Equity shares
01 Nov 2012 2.0 Interim 02 Nov 2012 Equity shares
20 Jul 2012 1.2 Final 24 Jul 2012 Equity shares
07 Feb 2012 1.0 Interim 2 08 Feb 2012 Equity shares
03 Nov 2011 1.0 Interim 07 Nov 2011 Equity shares
18 Jul 2011 1.2 Final 20 Jul 2011 Equity shares
01 Feb 2011 1.0 Interim 2 02 Feb 2011 Equity shares
28 Oct 2010 1.0 Interim 29 Oct 2010 Equity shares
16 Jul 2010 1.0 Final 20 Jul 2010 Equity shares
27 Jan 2010 4.0 Interim 2 28 Jan 2010 Equity shares
30 Oct 2009 5.0 Interim 03 Nov 2009 Equity shares
20 Jul 2009 4.0 Final 22 Jul 2009 Equity shares
27 Jan 2009 3.0 Interim 2 28 Jan 2009 Equity shares
07 Nov 2008 4.0 Interim 10 Nov 2008 Equity shares
14 Jul 2008 4.5 Final 16 Jul 2008 Equity shares
06 Nov 2007 3.5 Interim 07 Nov 2007 Equity shares
10 Jul 2007 4.0 Final 12 Jul 2007 Equity shares
02 Nov 2006 3.5 Interim 01 Jan 0001 Equity shares
09 Nov 2005 0.0 Interim 10 Nov 2005 Equity shares
13 Sep 2005 0.0 Final 15 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
31 Jan 2005 28 Jan 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Jan 2022 2.0 1.0 11 Jan 2022
22 Mar 2010 10.0 2.0 23 Mar 2010
Dividend date Dividend amount Dividend type Record date Instrument type
05 Aug 2025 2.0 Final 05 Aug 2025 Equity shares
27 Nov 2024 2.0 Interim 27 Nov 2024 Equity shares
06 Aug 2024 2.0 Final 07 Aug 2024 Equity shares
22 Nov 2023 2.0 Interim 22 Nov 2023 Equity shares
22 Nov 2022 4.0 Interim 23 Nov 2022 Equity shares
22 Nov 2021 8.0 Interim 23 Nov 2021 Equity shares
13 Nov 2020 8.0 Interim 17 Nov 2020 Equity shares
18 Feb 2020 5.0 Interim 20 Feb 2020 Equity shares
06 Aug 2019 3.0 Final 08 Aug 2019 Equity shares
02 Aug 2018 1.0 Final 04 Aug 2018 Equity shares
27 Jul 2017 1.0 Final 29 Jul 2017 Equity shares
22 Jul 2015 1.0 Final 24 Jul 2015 Equity shares
18 Jul 2014 2.5 Final 22 Jul 2014 Equity shares
31 Oct 2013 2.5 Interim 01 Nov 2013 Equity shares
19 Jul 2013 2.0 Final 23 Jul 2013 Equity shares
01 Nov 2012 2.0 Interim 02 Nov 2012 Equity shares
20 Jul 2012 1.2 Final 24 Jul 2012 Equity shares
07 Feb 2012 1.0 Interim 2 08 Feb 2012 Equity shares
03 Nov 2011 1.0 Interim 07 Nov 2011 Equity shares
18 Jul 2011 1.2 Final 20 Jul 2011 Equity shares
01 Feb 2011 1.0 Interim 2 02 Feb 2011 Equity shares
28 Oct 2010 1.0 Interim 29 Oct 2010 Equity shares
16 Jul 2010 1.0 Final 20 Jul 2010 Equity shares
27 Jan 2010 4.0 Interim 2 28 Jan 2010 Equity shares
30 Oct 2009 5.0 Interim 03 Nov 2009 Equity shares
20 Jul 2009 4.0 Final 22 Jul 2009 Equity shares
27 Jan 2009 3.0 Interim 2 28 Jan 2009 Equity shares
07 Nov 2008 4.0 Interim 10 Nov 2008 Equity shares
14 Jul 2008 4.5 Final 16 Jul 2008 Equity shares
06 Nov 2007 3.5 Interim 07 Nov 2007 Equity shares
10 Jul 2007 4.0 Final 12 Jul 2007 Equity shares
02 Nov 2006 3.5 Interim 01 Jan 0001 Equity shares
09 Nov 2005 0.0 Interim 10 Nov 2005 Equity shares
13 Sep 2005 0.0 Final 15 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
31 Jan 2005 28 Jan 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Jan 2022 2.0 1.0 11 Jan 2022
22 Mar 2010 10.0 2.0 23 Mar 2010

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Ipca Laboratories Ltd?

Answer Field

Ipca Laboratories Ltd share price is for NSE ₹ 1,524.40 & for BSE ₹ 1,512.90 as on May 29 2026 03:30 PM.

What is the Market Cap of Ipca Laboratories Ltd Share?

Answer Field

The market cap of Ipca Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 29 2026 03:30 PM.

What is the 52 Week High and Low of Ipca Laboratories Ltd?

Answer Field

The 52 Week High and Low of Ipca Laboratories Ltd for NSE is ₹ 1,678.30 and ₹ 1,251.60 and for BSE is ₹ 1,679.45 and ₹ 1,252.95.

What is 1 year return for Ipca Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 3.70%.

What is the P/E Ratio of Ipca Laboratories Ltd Share?

Answer Field

As on May 29 2026 03:30 PM the price-to-earnings (PE) ratio for Ipca Laboratories Ltd share is 47.67.

What is the PB ratio of Ipca Laboratories Ltd Share?

Answer Field

As on May 29 2026 03:30 PM, the price-to-book (PB) ratio for Ipca Laboratories Ltd share is 291.98.

How to Buy Ipca Laboratories Ltd Share?

Answer Field

You can trade in Ipca Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ipca Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Ipca Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ipca Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|